All stocks · GLPL
GP

GOLDLINE PHARMACEUTICAL LIMITED

GLPL BSE Pharmaceutical Retailers Healthcare

Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness…

ISIN INE1CLW01015
Listed —
Quarters tracked —
Filings 6 docs

About

Goldline Pharmaceutical Limited engages in marketing of pharmaceutical products under the Goldline brand in India. It offers goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty surgeons. It sells its products through distributors. The company was incorporated in 2004 and is based in Nagpur, India.

Quarterly Results

No quarterly results synced yet for this stock.

Data is backfilled from screener.in — check back soon.

Profit & Loss

Annual · Rs. Crores
Metric Mar 2026Mar 2025Mar 2024Mar 2023
Sales 31.1828.0123.4819.73
Expenses 24.0921.8619.1417.32
Operating Profit 7.096.154.342.41
OPM % 22.7421.9618.4812.21
Other Income 0.00-0.09-0.04-0.20
Interest 1.461.951.611.63
Depreciation 0.240.250.160.18
Profit before tax 5.393.862.530.40
Tax % 23.3826.4228.4637.50
Net Profit 4.122.831.810.26
EPS in Rs 5.974.107.871.30
Dividend Payout % 0.000.000.000.00

Balance Sheet

Annual · Rs. Crores — latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023
Equity Capital 6.906.902.302.00
Reserves 5.541.553.762.08
Borrowings 10.9712.8512.9412.64
Other Liabilities 5.474.883.932.67
Total Liabilities 28.8826.1822.9319.39
Fixed Assets 2.712.892.952.50
CWIP 0.000.000.450.00
Investments 0.030.030.030.07
Other Assets 26.1423.2619.5016.82
Total Assets 28.8826.1822.9319.39

Cash Flows

Annual · Rs. Crores — latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023
Cash from Operating Activity 2.813.182.922.39
Cash from Investing Activity -0.060.16-1.11-1.04
Cash from Financing Activity -3.40-2.89-1.08-1.44
Net Cash Flow -0.650.450.74-0.09
Free Cash Flow 2.753.351.811.38
CFO/OP % 53.0066.0072.00101.00

Ratios

Annual · Days / % — latest first
Metric Mar 2026Mar 2025Mar 2024Mar 2023
Debtor Days 188.82139.30149.54159.65
Inventory Days 202.38229.14450.39336.20
Days Payable 60.2969.6298.6254.47
Cash Conversion Cycle 330.91298.82501.32441.39
Working Capital Days 156.28133.57132.76143.74
ROCE % 30.6429.2823.40—

Shareholding Pattern

% holding — latest first
Holder May 2026
Promoters 57.29
FIIs 5.16
DIIs 7.81
Public 29.74
No. of Shareholders 271

Back to all stocks